Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 1NCT03819465
Official study title

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Study summary

This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDurvalumab and Danvatirsen

Plus 8 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 12, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?41 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
AstraZeneca
Interventions being studied
Drug: Durvalumab; Drug: Danvatirsen; Drug: Oleclumab; Drug: MEDI5752; Drug: Pemetrexed; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin; Drug: Nab-paclitaxel; Drug: AZD2936
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
  • No prior chemotherapy or any other systemic therapy for metastatic NSCLC
  • Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy
  • Known tumor PD-L1 status
  • Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
  • WHO/ECOG status at 0 or 1 at enrollment
  • Life expectancy of at least 12 weeks
  • Troponin I or T ≤ ULN (per institutional guidelines)
Reasons someone may not be able to joinExclusion criteria
  • Active or prior documented autoimmune or inflammatory disorders
  • History of active primary immunodeficiency
  • Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
  • Untreated CNS metastases

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteIowa City, Iowa
  • Research SitePittsburgh, Pennsylvania
  • Research SiteNashville, Tennessee
  • Research SiteSalzburg
  • Research SiteVienna
  • Research SiteEdegem
  • Research SiteBialystok
  • Research SiteBydgoszcz
  • Research SiteGdansk
  • Research SiteGrudziądz
  • Research SiteLodz
  • Research SiteOlsztyn

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2026. Always confirm current availability with the study team.

View original record ↗